Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3

Conditions

Thyroid Carcinoma, Anaplastic 4Thyroid Neoplasms 3Neuroendocrine Tumors 3Neoplasms 3Head and Neck Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × fosbretabulin × Clear all
NCT03014297 2019-08-08

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

University of Kentucky

Phase 1 Terminated
17 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02279602 2018-04-17

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Mateon Therapeutics

Phase 2 Completed
7 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Mateon Therapeutics

Phase 2 Completed
18 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡